SRR12202420
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.540
- INTERFERON_ALPHA_RESPONSE+0.400
- E2F_TARGETS+0.360
- INTERFERON_GAMMA_RESPONSE+0.340
- SPERMATOGENESIS+0.330
- INFLAMMATORY_RESPONSE+0.310
- IL6_JAK_STAT3_SIGNALING+0.260
- KRAS_SIGNALING_DN+0.260
- KRAS_SIGNALING_UP+0.260
- ALLOGRAFT_REJECTION+0.220
Top 10 suppressed
- NOTCH_SIGNALING-0.490
- WNT_BETA_CATENIN_SIGNALING-0.480
- MYC_TARGETS_V2-0.450
- P53_PATHWAY-0.370
- APICAL_JUNCTION-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- TGF_BETA_SIGNALING-0.320
- PI3K_AKT_MTOR_SIGNALING-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- MITOTIC_SPINDLE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516037 | — | — | 0.817 |
| 2 | C3L-02654 | — | cohortA1 | 0.792 |
| 3 | R212 | — | — | 0.763 |
| 4 | MNG1127 | — | — | 0.744 |
| 5 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.734 |
| 6 | TCGA-53-7813-01A-11R-2170-07 | — | cohortA3 | 0.733 |
| 7 | TCGA-NC-A5HJ-01A-11R-A26W-07 | — | cohortA1 | 0.733 |
| 8 | SRR1382869 | GTEX | — | 0.728 |
| 9 | TCGA-4Z-AA7Q-01A-11R-A39I-07 | — | — | 0.721 |
| 10 | SRR2932829 | — | — | 0.717 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.540 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |